, Tracking Stock Market Picks
Enter Symbol:
Aegerion Pharmaceuticals, Inc. (AEGR) [hlAlert]

down 47.61 %

Aegerion Pharmaceuticals, Inc. (AEGR) rated Buy by BofA/Merrill

Posted on: Tuesday,  Mar 5, 2013  8:25 AM ET by BofA/Merrill

BofA/Merrill rated Buy Aegerion Pharmaceuticals, Inc. (NASDAQ: AEGR) on 03/05/2013, when the stock price was $33.90. Since
then, Aegerion Pharmaceuticals, Inc. has lost 47.61% as of 01/27/2016's recent price of $17.76.
If you would have followed this BofA/Merrill's recommendation on AEGR, you would have lost 47.61% of your investment in 1058 days.

Aegerion Pharmaceuticals, Inc. (Aegerion) is a biopharmaceutical company focused on the development and commercialization of therapeutics to treat severe lipid disorders. Its lead compound, lomitapide, is a microsomal triglyceride transfer protein inhibitor (MTP-I), which limits secretion of cholesterol and triglycerides from the intestines and the liver, the main sources of lipids in the body. The Company is initially developing lomitapide as an oral, once-a-day treatment for patients with a rare genetic lipid disorder called homozygous familial hypercholesterolemia (HoFH). HoFH is a genetic lipid disorder caused by defects in both copies of the low-density lipoprotein (LDL) receptor genes, resulting in impaired or total loss of function in the LDL receptor.

Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/5/2013 8:25 AM Buy
as of 12/13/2013
1 Week down  -1.19 %
1 Month down  -19.47 %
3 Months down  -27.29 %
1 YTD up  95.28 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy